<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Oncology</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Oncology</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский онкологический журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1028-9984</issn><issn publication-format="electronic">2412-9119</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">40369</article-id><article-id pub-id-type="doi">10.18821/1028-9984-2017-22-2-84-88</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">THE ADVANTAGE OF THE TRANSRADIAL APPROACH FOR PROSTATE ARTERY EMBOLIZATION</article-title><trans-title-group xml:lang="ru"><trans-title>ПРЕИМУЩЕСТВА ТРАНСРАДИАЛЬНОГО СОСУДИСТОГО ДОСТУПА ПРИ ЭМБОЛИЗАЦИИ ПРОСТАТИЧЕСКИХ АРТЕРИЙ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Khayrutdinov</surname><given-names>E. R</given-names></name><name xml:lang="ru"><surname>Хайрутдинов</surname><given-names>Евгений Рафаилович</given-names></name></name-alternatives><bio xml:lang="ru"><p>канд. мед. наук, врач-рентгенолог отделения рентгенохирургических методов диагностики и лечения ГКБ им. С.П. Боткина ДЗ г. Москвы</p></bio><email>eugkh@yandex.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Vorontsov</surname><given-names>I. M</given-names></name><name xml:lang="ru"><surname>Воронцов</surname><given-names>И. М</given-names></name></name-alternatives><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Zharikov</surname><given-names>S. B</given-names></name><name xml:lang="ru"><surname>Жариков</surname><given-names>С. Б</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Arablinskiy</surname><given-names>A. V</given-names></name><name xml:lang="ru"><surname>Араблинский</surname><given-names>А. В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Ignatiev</surname><given-names>Yu. T</given-names></name><name xml:lang="ru"><surname>Игнатьев</surname><given-names>Ю. Т</given-names></name></name-alternatives><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Leonov</surname><given-names>O. V</given-names></name><name xml:lang="ru"><surname>Леонов</surname><given-names>О. В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff4"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">S.P. Botkin City Clinical Hospital</institution></aff><aff><institution xml:lang="ru">ГБУЗ «Городская клиническая больница им. С.П. Боткина» Департамента здравоохранения города Москвы</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">City Clinical Emergency Hospital №1</institution></aff><aff><institution xml:lang="ru">БУЗ Омской области «Городская клиническая больница скорой медицинской помощи № 1»</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Omsk State Medical Academy</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">Clinical Oncology Dispensary</institution></aff><aff><institution xml:lang="ru">БУЗ Омской области «Клинический онкологический диспансер»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2017-04-15" publication-format="electronic"><day>15</day><month>04</month><year>2017</year></pub-date><volume>22</volume><issue>2</issue><issue-title xml:lang="en">VOL 22, NO2 (2017)</issue-title><issue-title xml:lang="ru">ТОМ 22, №2 (2017)</issue-title><fpage>84</fpage><lpage>88</lpage><history><date date-type="received" iso-8601-date="2020-07-22"><day>22</day><month>07</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2017, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2017, ООО "Эко-Вектор"</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">ООО "Эко-Вектор"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://rjonco.com/1028-9984/article/view/40369">https://rjonco.com/1028-9984/article/view/40369</self-uri><abstract xml:lang="en"><p>Treatment of benign prostatic hyperplasia is an important and challenging problem of modern medicine. One of the most modern methods of the treatment of this disease is prostatic artery embolization. This procedure is most often done through transfemoral approach. Transradial vascular access has many advantages over the transfemoral access. Our study presents a comparative analysis of the use of transradial and transfemoral approach in this type of interventions. Transradial access was used in 13 patients, and transfemoral access - in 12 patients. The success of the procedure was 100% in both groups. The total duration of the procedure, the time needed for catheterization of internal iliac and prostatic arteries and the radiation exposure were significantly lower in the transradial approach group. There were no significant differences in the incidence of complications between two groups. The use of the transradial access was associated with a significant reduction of the frequency and severity of the discomfort associated with the procedure. Transradial approach has numerous advantages over the transfemoral approach and may have great clinical significance.</p></abstract><trans-abstract xml:lang="ru"><p>Лечение доброкачественной гиперплазии предстательной железы является важной и актуальной проблемой современной медицины. Один из наиболее современных методов лечения данного заболевания - эмболизация простатических артерий, которая, как правило, проводится через трансфеморальный доступ. Трансрадиальный сосудистый доступ обладает многочисленными преимуществами перед трансфеморальным доступом. Представлен сравнительный анализ использования трансрадиального и трансфеморального доступа при проведении данного вида вмешательств. В группу трансрадиального доступа вошло 13, а в группу трансфеморального доступа - 12 пациентов. Успех процедуры составил 100% в обеих группах. Общая продолжительность процедуры, время, потраченное на катетеризацию внутренних подвздошных и простатических артерий, а также лучевая нагрузка были достоверно ниже в группе трансрадиального доступа. Достоверные различия в частоте осложнений со стороны сосудистого доступа отсутствовали. Использование трансрадиального доступа сопровождалось достоверным снижением частоты развития и выраженности дискомфорта, связанного с процедурой. Таким образом, трансрадиальный доступ обладает многочисленными преимуществами по сравнению с трансфеморальным доступом и может иметь большую клиническую значимость.</p></trans-abstract><kwd-group xml:lang="en"><kwd>prostate artery embolization</kwd><kwd>transradial approach</kwd><kwd>transfemoral approach</kwd><kwd>benign prostatic hyperplasia</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>эмболизация простатических артерий</kwd><kwd>трансрадиальный доступ</kwd><kwd>трансфеморальный доступ</kwd><kwd>доброкачественная гиперплазия предстательной железы</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Lee C., Kozlowski J.M., Grayhack J.T. Intrinsic and extrinsic factors controlling benigh prostatic growth. Prostate. 1997; 31(2): 131-8.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>American Urological Association: Guideline: Management of Benigh Prostatic Hyperplasia (BPH). Revised, 2010.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Appleton D.S., Sibley G.N., Doyle P.T. Internal iliac artery embolisation for the control of severe bladder and prostate haemorrhage. Br. J. Urol. 1988; 61(1): 45-7.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Michel F., Dubruille T., Cercueil J.P. et al. Arterial embolization for massive hematuria following transurethral prostatectomy. J. Urol. 2002; 168(6): 2550-1.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Rastinehad A.R., Caplin D.M., Ost M.C. et al. Selective arterial prostatic embolization (SAPE) for refractory hematuria of prostatic origin. Urology. 2008; 71(2): 181-4.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>DeMeritt J.S., Elmasri F.F., Esposito M.P. et al. Relief of benign prostatic hyperplasia-related bladder outlet obstruction after transarterial polyvinyl alcohol prostate embolization. J. Vasc. Interv. Radiol. 2000; 11(6): 767-70.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Carnevale F.C., Antunes A.A., da Motta Leal Filho J.M. et al. Prostatic artery embolization as a primary treatment for benign prostatic hyperplasia: preliminary results in two patients. Cardiovasc. Interv. Radiol. 2010; 33(2): 355-61.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Worthington-Kirsch R.L., Andrews R.T., Siskin G.P. et al. Uterine fibroid embolization: technical aspects. Tech. Vasc. Interv. Radiol. 2002; 5: 17-34.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Carnevale F.C., da Motta-Leal-Filho J.M., Antunes A.A. et al. Quality of life and symptoms relief support prostatic artery embolization for patients with acute urinary retention due to benign prostatic hyperplasia. J. Vasc. Interv. Radiol. 2012; 24: 535-42.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Bilhim T., Pisco J., Rio Tinto H. et al. Unilateral versus bilateral prostatic arterial embolization for lower urinary tract symptoms in patients with prostate enlargement. Cardiovasc. Interv. Radiol. 2013; 36(2): 403-11.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Mclvor J., Rhymer J.C. 245 transaxillary arteriograms in arteriopathic patients: success rate and complications. Clin. Radiol. 1992; 45(6): 390-4.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Jolly S.S., Yusuf S., Cairns J. et al. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet. 2011; 377(9775): 1409-20.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Tavris D.R., Gallauresi B.A., Lin B. et al. Risk of local adverse events following cardiac catheterisation by hemostasis device use and gender. J. Invasive Cardiol. 2004; 16(9): 459-64.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Kanei Y., Kwan T., Nakra N.C. et al. Transradial cardiac catheterization: A review of access site complications. Catheter. Cardiovasc. Interv. 2011; 78(6): 840-6.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Caputo R.P., Tremmel J.A., Rao S. et al. Transradial arterial access for coronary and peripheral procedures: Executive summary by the transradial committee of the SCAI. Catheter. Cardiovasc. Interv. 2011; 78(6): 823-39.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Sherev D.A., Shaw R.E., Brent B.N. Angiographic predictors of femoral access site complications: implication for planned percutaneous coronary intervention. Catheter. Cardiovasc. Interv. 2005; 65(2): 196-202.</mixed-citation></ref></ref-list></back></article>
